Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.4K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Prevention02:59

Cancer Prevention

8.7K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.7K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.

Leukemia·2016
Same author

pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.

Blood cancer journal·2015
Same author

Frequent expression of HAGE in presentation chronic myeloid leukaemias.

Leukemia·2002
Same author

Deregulated expression of promyelocytic leukemia zinc finger protein in B-cell chronic lymphocytic leukemias does not affect cyclin A expression.

The hematology journal : the official journal of the European Haematology Association·2002
Same author

H RAS mutations in haematologically normal individuals.

The hematology journal : the official journal of the European Haematology Association·2002
Same author

Retinoic acid receptor alpha1 variants, RARalpha1DeltaB and RARalpha1DeltaBC, define a new class of nuclear receptor isoforms.

Nucleic acids research·2002
Same journal

[Risk of transmission of blood-derived pathogens by transfusion in Poland].

Acta haematologica Polonica·2020
Same journal

[Emerging infectious diseases in the context of blood safety].

Acta haematologica Polonica·2020
Same journal

<i>Quo Vadis</i> medycyno regeneracyjna?: Quo Vadis Regenerative Medicine?

Acta haematologica Polonica·2013
Same journal

[RHnull syndrome--diagnostic and therapeutic problems].

Acta haematologica Polonica·1996
Same journal

[Unclassified chronic myeloproliferative Ph(-); i(17q); +8 syndrome with mixed myelo-megakaryoblastic crisis--case report].

Acta haematologica Polonica·1996
Same journal

Acute myelofibrosis in children: report on two cases.

Acta haematologica Polonica·1996
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

Genetic lesions in preleukemia

R A Padua1

  • 1Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, U.K.

Acta Haematologica Polonica
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Genetic abnormalities like RAS and p53 mutations are observed in pre-leukemic states, including myelodysplastic syndromes (MDS). A prospective study aims to determine if these genetic markers predict leukemia development.

More Related Videos

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.6K
Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

84.4K

Related Experiment Videos

Last Updated: Mar 24, 2026

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.6K
Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

84.4K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Preleukemic states, such as myelodysplastic syndromes (MDS), are characterized by genetic abnormalities.
  • Patients at risk for secondary leukemia or disease progression exhibit genetic alterations.
  • The timing of genetic abnormality detection post-treatment may indicate clone expansion.

Purpose of the Study:

  • To investigate the incidence of genetic abnormalities in preleukemic conditions.
  • To evaluate the prognostic significance of genetic markers in leukemia development.
  • To analyze genetic profiles in patients with myelodysplastic syndromes and those at risk for leukemia.

Main Methods:

  • Analysis of genetic abnormalities including RAS and FMS oncogene mutations, p53 suppressor gene mutations, and monoclonality.
  • Study of patients with myelodysplastic syndromes (MDS) and hematologically normal individuals in remission from lymphoma.
  • Case study of non-dysplastic MDS with a 7q-karyotypic abnormality, abnormal progenitor growth, and RAS mutations.

Main Results:

  • RAS and FMS oncogene mutations, p53 suppressor gene mutations, and monoclonality were observed in preleukemic states like MDS.
  • A case of non-dysplastic MDS presented with a 7q-karyotypic abnormality, abnormal progenitor growth, and RAS mutations, despite normal clinical features.
  • Normal individuals showed a low incidence of proto-oncogene mutations.

Conclusions:

  • Genetic abnormalities are prevalent in preleukemic conditions and may be associated with disease progression.
  • Further prospective studies are needed to confirm the prognostic value of these genetic parameters in predicting leukemia.
  • Understanding these genetic alterations is crucial for identifying individuals at high risk for developing leukemia.